Biotech stock Travere Therapeutics is trading at a deep discount: JPMorgan

July 21, 2023 07:12 PM BST | By Invezz
 Biotech stock Travere Therapeutics is trading at a deep discount: JPMorgan
Image source: Invezz

Travere Therapeutics Inc (NASDAQ: TVTX) has been a disappointment for shareholders since early May but a JPMorgan analyst expects it to recover over the next 18 months.

Travere Therapeutics shares have a 65% upside

On Friday, Anupam Rama assumed coverage of the biotech stock with an “overweight” rating. His $26 price objective signals a whopping 65% upside from here.

The analyst recommends buying Travere Therapeutics shares for “Filspari” – its treatment for a rare kidney disease called immunoglobulin A nephropathy that received accelerated FDA approval earlier this year.

We see IgAn market as a large multi-billion long-term market that can support multiple innovative therapies/modalities, for which Filspari should have a meaningful place in the treatment paradigm.

The biopharmaceutical company is expected to lose $1.15 a share in its currently financial quarter versus $1.05 per share a year ago.

Why else is he bullish on the biotech stock?

Anupam Rama is bullish on Travere Therapeutics shares also for “Pegtibatinase” that he dubbed a compelling product in his research note on Friday.

Pegtibatinase is treatment for a genetic metabolic disorder called Classical Homocystinuria and is currently awaiting regulatory feedback. According to the JPMorgan analyst:

Looking at the pipeline more broadly, the Pegtibatinase opportunity is being significantly underappreciated by the Street, and this program has the potential as a long-term game changer in HCU.

All in all, he said a near 30% plunge in the biotech stock in less than three months warrants an investment. Travere Therapeutics is scheduled to report its second-quarter financial results in the first week of August.

The post Biotech stock Travere Therapeutics is trading at a deep discount: JPMorgan appeared first on Invezz.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Limited, Company No. 12643132 (Kalkine Media, we or us) and is available for personal and non-commercial use only. Kalkine Media is an appointed representative of Kalkine Limited, who is authorized and regulated by the FCA (FRN: 579414). The non-personalised advice given by Kalkine Media through its Content does not in any way endorse or recommend individuals, investment products or services suitable for your personal financial situation. You should discuss your portfolios and the risk tolerance level appropriate for your personal financial situation, with a qualified financial planner and/or adviser. No liability is accepted by Kalkine Media or Kalkine Limited and/or any of its employees/officers, for any investment loss, or any other loss or detriment experienced by you for any investment decision, whether consequent to, or in any way related to this Content, the provision of which is a regulated activity. Kalkine Media does not intend to exclude any liability which is not permitted to be excluded under applicable law or regulation. Some of the Content on this website may be sponsored/non-sponsored, as applicable. However, on the date of publication of any such Content, none of the employees and/or associates of Kalkine Media hold positions in any of the stocks covered by Kalkine Media through its Content. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music/video that may be used in the Content are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music or video used in the Content unless stated otherwise. The images/music/video that may be used in the Content are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Sponsored Articles


Investing Ideas

Previous Next